Figure 3.

Effect of BMP pathway inhibition on CGRP-induced MG-63 cell proliferation and BMP-2 expression. MG-63 cells were pre-treated with BMP pathway inhibitors (100 ng/mL Noggin) before treatment with 10⁻⁸ mol/L CGRP. (A) Flow cytometry analysis of the cell cycle in four groups. (B) The percentages of Noggin pre-treated, CGRP-induced MG-63 cells at the S/G₂ phase are not significantly different from the CGRP group, but a significant difference between the Noggin pre-treated and non-induced control group (P<0.05). Results are shown as mean±SD of 4 independent samples.